Compare Abeona Therapeutics Inc (ABEO) vs Health Care Select Sector SPDR Fund (XLV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Health Care Select Sector SPDR Fund — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while Health Care Select Sector SPDR Fund trades at $163.19. The key difference: Health Care Select Sector SPDR Fund is trading nearer its 52-week high, Abeona Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | XLV | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | — |
52-Week High | $7.23 | $164.48 |
52-Week Low | $4.17 | $129.01 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
XLV trades at $162.06, down 1.03% on the day, with technical indicators showing a bullish trend supported by moving averages while oscillators remain neutral. The healthcare ETF benefits from defensive sector positioning amid market volatility, with recent news highlighting healthcare as a safe haven during choppy markets. A dividend of $0.66 is scheduled for June 2026, providing income appeal.
Outlook remains positive given healthcare's defensive characteristics and innovation momentum in biotech and pharmaceuticals. Key risks include sector-specific regulatory pressures and patent cliff concerns for major holdings. Analyst sentiment leans bullish with technical support at $160 and resistance at $164.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Health Care Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →
